Българска кардиология (Jun 2022)

TAVI in bicuspid aortic valve

  • I.N. Dimitrova,
  • J. Jorgova,
  • P. Simeonov,
  • H. Angelov,
  • D. Trendafilova

DOI
https://doi.org/10.3897/bgcardio.28.e82418
Journal volume & issue
Vol. 28, no. 2
pp. 7 – 18

Abstract

Read online Read online Read online

Transcatheter aortic valve implantation (TAVI) is an established choice for the treatment of severe aortic stenosis (AS) in patients who are deemed inoperable or at high surgical risk. There are limited data for the safety and effi cacy of the method in patients with bicuspid aortic valve (BAV), the most common congenital valve defect. Patients with BAV were excluded from randomized clinical trials (RCTs), comparing TAVI to surgery due to the heterogeneous anatomy of this nosological unit and concerns about unsatisfactory procedural and clinical outcomes after TAVI. With the improvement of the design of the new generations devices, with the growing technical experience of the teams and the progress in the imaging techniques, better results and fewer complications are observed, which could be a prerequisite for expanding the indications for TAVI in patients with BAV. This review presents TAVI treatment options for patients with BAV, the results of available registers in terms of safety and effi cacy of the procedure, and future perspectives.

Keywords